Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

INDUSTRY × Cilengitide × Thoracic × Clear all

Phase

Status

Sponsor Class

OTHER 1 INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 2 Thoracic 1 Lymphoid 1

Conditions

Metatropic dwarfism 1 Carcinoma, Non-Small-Cell Lung 1

Interventions

Carboplatin 476 Pemetrexed 337 pembrolizumab 321 Cisplatin 319 Paclitaxel 251 Docetaxel 217 Gemcitabine 142 Nivolumab 138 Erlotinib Hydrochloride 130 Bevacizumab 102 atezolizumab 91 osimertinib 88 durvalumab 86 Etoposide 79 Gefitinib 62 Cetuximab 57 130-nm albumin-bound paclitaxel 57 Ipilimumab 48 Drug Therapy 48 Topotecan 42 Afatinib 37 Injections 36 Cyclophosphamide 36 tislelizumab 35 Albumin-Bound Paclitaxel 33 Vinorelbine 32 Crizotinib 30 cemiplimab 27 icotinib 25 Radiotherapy 25

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT00842712 2017-01-13

CERTO

Merck KGaA, Darmstadt, Germany

Phase 2 Completed

232 enrolled 17 charts

Metatropic dwarfism, Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon ⚡